Sanofi Sponsored ADR Aktie News

NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidara th...

Biotech stock Dynavax Technologies Corp (NASDAQ:DVAX) is soaring today, last seen up 38.7% at $15.43, after reports that Sanofi (SNY) plans to acquire the company in an all-cash deal worth roughly $2.2 billion.

French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult immunization market. Under the agreement, Sanofi will launch a cash tender offer of $15.50 per Dynavax share, representing a 39% premium to the company's pre-deal stock price.

Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

Sanofi will buy vaccine maker Dynavax Technologies for $2.2 billion, or $15.50 a share, adding to its adult immunizations. Dynavax stock soared.

French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.

The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.